# US 2013/0251697 A1 · Novel nasal spray

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251697 A1
- Document ID: US20130251697A1
- Status: Published application
- Kind: A1
- Application number: 13/706,085
- Filed: 2012-12-05
- Published: 2013-09-26
- Earliest claimed: 2009-06-15
- Inventors: Ford D. Albritton, IV
- Web page: https://patentgrep.com/patent/US20130251697A1

## CPC

- A61K 36/82: Theaceae (Tea family), e.g. camellia
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/09: having two or more such linkages
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/385: having two or more sulfur atoms in the same ring
- A61K 33/30: Zinc; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Systems and methods are disclosed for treating a plurality of sinsousal conditions to be treated. These systems and methods include selecting a combination of at least two compounds that are capable of addressing a plurality of sinsousal conditions. At least one of the at least two compounds is selected from a group of anti fungals, antioxidants, and chelators. These systems and methods also include verifying that the compounds are biologically compatible and creating a combination compound using the selected compounds.

## Claims

### Claim at position 1

-13. (canceled)

### Claim 14

A chemical composition, comprising:
a combination of at least two compounds, capable of addressing a plurality of sinonasal conditions, wherein at least one of the at least two compounds is selected from a group of anti fungals, antioxidants, and chelators, and wherein the at least two compounds are biologically compatible; and wherein the composition comprises quercetin chalcone and resveratrol.

### Claim 15 (depends on 14)

The composition in accordance with claim 14, wherein the composition comprises epigallocatechin gallate (ECGC).

### Claim 16 (depends on 14)

The composition in accordance with claim 14 wherein the composition further comprises: monolauren, epigallocatechin gallate (ECGC), lipoic acid, acetyl-c-cysteine and zinc.

### Claim 17

A chemical composition, comprising:
a combination of biologically compatible compounds operable for addressing a plurality of sinonasal conditions, the combination of compounds comprising:
an anti fungal;
at least one antioxidant; and
a chelator.

### Claim 18 (depends on 17)

The composition in accordance with claim 17 wherein the combination of compounds comprises: resveratrol, quercetin, acetyl carnitine and green tea extract.

### Claim 19 (depends on 18)

The composition in accordance with claim 18 wherein the resveratrol, quercetin, acetyl carnitine and green tea extract together comprise approximately between 0.2% and 5% of the combination of compounds.

### Claim 20 (depends on 17)

The composition in accordance with claim 17 wherein the antifungal comprises monolauren.

### Claim 21 (depends on 20)

The composition in accordance with claim 20 wherein the chelator comprises zinc.

### Claim 22 (depends on 21)

The composition in accordance with claim 21 wherein the combination of compounds further comprises lipoic acid.

### Claim 23 (depends on 18)

The composition in accordance with claim 18 wherein the quercetin is in the form of quercetin chalcone powder in an amount of approximately 0.3% of the combination of compounds.

### Claim 24 (depends on 23)

The composition in accordance with claim 23 wherein the resveratrol is in an amount of approximately 0.15% of the combination of compounds.

### Claim 25 (depends on 24)

The composition in accordance with claim 24 wherein the combination of compounds further comprises approximately 2% xylitol.

### Claim 26

A chemical composition, comprising:
a combination of biologically compatible compounds operable for addressing a plurality of sinonasal conditions, the combination of compounds comprising:
an anti fungal;
a group of antioxidants, the group of antioxidants comprising at least three antioxidants; and
a chelator.

### Claim 27 (depends on 26)

The composition in accordance with claim 26 wherein the group of antioxidants comprises quercetin, resveratrol, and epigallocatechin gallate (ECGC), and the combination of compounds further comprises: lipoic acid, ascorbic acid, glutathione, acetyl-c-cysteine and xylitol.

### Claim 28 (depends on 27)

The composition in accordance with claim 27 wherein the anti fungal comprises monolauren and the chelator comprises zinc.

### Claim 29 (depends on 26)

The composition in accordance with claim 26 wherein the combination of compounds comprises;
quercetin in an amount of approximately 0.3% of the combination of compounds;
resveratrol is in an amount of approximately 0.15% of the combination of compounds;
lipoic acid in an amount of approximately 0.3% of the combination of compounds;
glutathione in an amount of approximately 0.3% of the combination of compounds;
acetyl-c-cysteine in an amount of approximately 0.3% of the combination of compounds; and
zylitol in an amount of approximately 2% of the combination of compounds.
